Systematic Review: Cardiac Resynchronization in Patients with Symptomatic Heart Failure

  1. Finlay A. McAlister, MD, MSc;
  2. Justin A. Ezekowitz, MB, BCh, MSc;
  3. Natasha Wiebe, Mmath;
  4. Brian Rowe, MD, MSc;
  5. Carol Spooner, MSc;
  6. Ellen Crumley, MLIS;
  7. Lisa Hartling, MSc;
  8. Terry Klassen, MD, MSc; and
  9. William Abraham, MD
  1. From The University of Alberta and Capital Health Evidence-based Practice Center, Edmonton, Alberta, Canada; and Ohio State University, Columbus, Ohio.
    1. Figure 1. FDA = U.S. Food and Drug Administration.
      View larger version:
      Figure 1. FDA = U.S. Food and Drug Administration. Flow diagram of study selection.
    2. Figure 2. CHF = congestive heart failure; COMPANION = Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure; CONTAK CD = Guidant CONTAK CD CRT-D System Trial; MIRACLE = Multicenter InSync Randomized Clinical Evaluation; MIRACLE-ICD = Multicenter InSync Randomized Clinical Evaluation ICD [implantable cardioverter-defibrillator]; MUSTIC-AF = Multisite Stimulation in Cardiomyopathies Atrial Fibrillation; MUSTIC-SR = Multisite Stimulation in Cardiomyopathies Sinus Rhythm; PATH-CHF = Pacing Therapies for Congestive Heart Failure; RR = relative risk.
      View larger version:
      Figure 2. CHF = congestive heart failure; COMPANION = Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure; CONTAK CD = Guidant CONTAK CD CRT-D System Trial; MIRACLE = Multicenter InSync Randomized Clinical Evaluation; MIRACLE-ICD = Multicenter InSync Randomized Clinical Evaluation ICD [implantable cardioverter-defibrillator]; MUSTIC-AF = Multisite Stimulation in Cardiomyopathies Atrial Fibrillation; MUSTIC-SR = Multisite Stimulation in Cardiomyopathies Sinus Rhythm; PATH-CHF = Pacing Therapies for Congestive Heart Failure; RR = relative risk. All-cause mortality with cardiac resynchronization therapy (CRT) versus controls.
    3. Figure 3. CHF = congestive heart failure; CONTAK-CD = Guidant CONTAK CD CRT-D System Trial; MIRACLE = Multicenter InSync Randomized Clinical Evaluation; MIRACLE-ICD = Multicenter InSync Randomized Clinical Evaluation ICD [implantable cardioverter-defibrillator]; MUSTIC- AF = Multisite Stimulation in Cardiomyopathies Atrial Fibrillation; MUSTIC-SR = Multisite Stimulation in Cardiomyopathies Sinus Rhythm; RR = relative risk.
      View larger version:
      Figure 3. CHF = congestive heart failure; CONTAK-CD = Guidant CONTAK CD CRT-D System Trial; MIRACLE = Multicenter InSync Randomized Clinical Evaluation; MIRACLE-ICD = Multicenter InSync Randomized Clinical Evaluation ICD [implantable cardioverter-defibrillator]; MUSTIC- AF = Multisite Stimulation in Cardiomyopathies Atrial Fibrillation; MUSTIC-SR = Multisite Stimulation in Cardiomyopathies Sinus Rhythm; RR = relative risk. Heart failure hospitalizations with cardiac resynchronization therapy (CRT) versus controls.
    4. Figure 4. CHF = congestive heart failure; COMPANION = Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure; CONTAK- CD = Guidant CONTAK CD CRT-D System Trial; MIRACLE = Multicenter InSync Randomized Clinical Evaluation; MIRACLE-ICD = Multicenter InSync Randomized Clinical Evaluation ICD [implantable cardioverter-defibrillator]; MUSTIC-AF = Multisite Stimulation in Cardiomyopathies Atrial Fibrillation; MUSTIC-SR = Multisite Stimulation in Cardiomyopathies Sinus Rhythm; PATH-CHF = Pacing Therapies for Congestive Heart Failure.
      View larger version:
      Figure 4. CHF = congestive heart failure; COMPANION = Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure; CONTAK- CD = Guidant CONTAK CD CRT-D System Trial; MIRACLE = Multicenter InSync Randomized Clinical Evaluation; MIRACLE-ICD = Multicenter InSync Randomized Clinical Evaluation ICD [implantable cardioverter-defibrillator]; MUSTIC-AF = Multisite Stimulation in Cardiomyopathies Atrial Fibrillation; MUSTIC-SR = Multisite Stimulation in Cardiomyopathies Sinus Rhythm; PATH-CHF = Pacing Therapies for Congestive Heart Failure. Changes in quality of life with cardiac resynchronization therapy (CRT) versus controls (based on the Minnesota Living with Heart Failure [MLWHF] Questionnaire).

    Responses to this article

    • Is the NNTb quoted a point estimate or one end point of CI
      • Ian TF Cheung
      Ann Intern Med published online October 26, 2009
    • Reply to letters
      • Finlay A. McAlister and
      • Natasha Wiebe, William Abraham
      Ann Intern Med published online October 26, 2009
    • Cardiac Resynchronization in Patients with Symptomatic Heart Failure
      • Melanie J. Calvert and
      • Nick Freemantle, and John G.F. Cleland
      Ann Intern Med published online October 26, 2009
    • Cardiac resynchronization therapy in heart failure
      • Enrique V. Carbajal and
      • Grace W. Huang, Billy Hu
      Ann Intern Med published online October 26, 2009
    « Previous | Next Article »Table of Contents

    This Article

    1. Ann Intern Med September 7, 2004 vol. 141 no. 5 381-390
    1. AbstractFREE
    2. » Figures
    3. Full Text
    4. Full Text (PDF)

    Current Issue

    1. November 3, 2009, 151 (9)
    1. Alert me to current issues